Evaluation of the disposition and mass balance recovery of vebicorvir, a first-generation hepatitis B core inhibitor, in rats and humans

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022


Evaluation of the disposition and mass balance recovery of vebicorvir, a first-generation hepatitis B core inhibitor, in rats and humans

	EASL 2022 June 22-26 London Katie Zomorodi, Luisa M. Stamm, William Delaney, Michael Shen Assembly Biosciences, Inc., South San Francisco, CA, USA